Tufts Medical Center, Boston, Massachusetts.
New York University Langone Health, New York.
Arthritis Care Res (Hoboken). 2020 Sep;72(9):1282-1288. doi: 10.1002/acr.24026.
To evaluate the longitudinal responsiveness (sensitivity to change) of the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Short Form (PROMIS10) in outpatients with systemic lupus erythematosus (SLE).
Outpatients with SLE who were receiving care at an academic medical center completed the PROMIS10 at 2 visits that were a minimum of 1 month apart. Responsiveness of the PROMIS10 global physical and mental health domains to Patient-Reported improvement or deterioration of health status was evaluated, as measured by standard validated instruments. Effect sizes of changes in PROMIS10 scores between visits were evaluated using Kruskal-Wallis testing.
A total of 223 SLE patients enrolled and completed baseline surveys, with 186 (83.4%) completing a second set of questionnaires. The PROMIS10 demonstrated mild-to-moderate responsiveness to Patient-Reported improvement (effect size 0.29) and worsening (effect sizes -0.27 and -0.54) of health status for both global physical health and global mental health. Changes in the PROMIS10 correlated poorly with changes in physician-reported measures of disease activity.
The PROMIS10 showed responsiveness over time to Patient-Reported changes in SLE health status, but not physician-assessed changes. These data suggest that the PROMIS10 can be used to efficiently measure and monitor important aspects of the SLE patient experience that are not captured by standard physician-derived metrics. Further studies are needed to evaluate the role of the PROMIS10 in optimizing longitudinal disease management in SLE and to determine its responsiveness in other chronic health conditions.
评估患者报告结局测量信息系统（PROMIS）全球健康简短量表（PROMIS10）在系统性红斑狼疮（SLE）门诊患者中的纵向反应性（变化敏感性）。
在学术医疗中心接受治疗的 SLE 门诊患者在至少相隔 1 个月的 2 次就诊时完成了 PROMIS10。通过标准验证工具评估 PROMIS10 全球身体和心理健康领域对患者报告的健康状况改善或恶化的反应性。使用 Kruskal-Wallis 检验评估两次就诊之间 PROMIS10 评分变化的效应大小。
共有 223 名 SLE 患者入组并完成了基线调查，其中 186 名（83.4%）完成了第二套问卷。PROMIS10 对患者报告的健康状况改善（效应大小 0.29）和恶化（全球身体和全球心理健康的效应大小分别为-0.27 和-0.54）具有轻度至中度反应性。PROMIS10 的变化与医生报告的疾病活动度测量值的变化相关性较差。
PROMIS10 随着时间的推移对 SLE 健康状况的患者报告变化具有反应性，但对医生评估的变化没有反应性。这些数据表明，PROMIS10 可用于有效地测量和监测 SLE 患者体验中未被标准医生衍生指标捕捉到的重要方面。需要进一步的研究来评估 PROMIS10 在 SLE 纵向疾病管理中的作用，并确定其在其他慢性健康状况中的反应性。
